Brought to you by 
PanOptica brings in $30mm through its Series A round
16 Apr 2014
Executive Summary
PanOptica Inc. (ophthalmic therapeutics) raised $30mm through its Series A venture round. SV Life Sciences and Third Rock Ventures co-led (and will contribute board members) and were joined by three undisclosed investors. When the transaction was publicly announced in January 2011, PanOptica licensed exclusive global rights to OSI Pharmaceuticals’ PAN90806, a VEGF inhibitor for neovascular age-related macular degeneration. Some funds will be used to bring the candidate through Phase II, license and advance another AMD compound through Phase II, and select a third program.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PanOptica brings in $30mm through its Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice